Searching for biomarker patterns characterizing carotid atherosclerotic burden in patients with reduced renal function

Nephrology Dialysis Transplantation

Volumn 22, Issue 12, 2007, Pages 3521-3526

  Addabbo, Francesco ^a   Mallamaci, Francesca ^b   Leonardis, Daniela ^b   Tripepi, Rocco ^b   Tripepi, Giovanni ^b   Goligorsky, Michael S ^a   Zoccali, Carmine ^b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b CNR   (Italy)

Author keywords

Atherosclerosis; Chronic kidney disease; Cytokines; IL 6; MMP 9; Multiplexed analysis

Indexed keywords

ANGIOGENIC FACTOR; ANTIFIBRINOLYTIC AGENT; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; GELATINASE B; INTERLEUKIN 6; INTERLEUKIN 8; N TERMINAL PROHORMONE BRAIN NATRIURETIC PEPTIDE; PEPTIDE; PLASMINOGEN ACTIVATOR INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ANALYTIC METHOD; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CHRONIC KIDNEY DISEASE; COLOR ULTRASOUND FLOWMETRY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; SCORING SYSTEM; UNIVARIATE ANALYSIS;

ADULT; BIOLOGICAL MARKERS; CAROTID ARTERY DISEASES; CHRONIC DISEASE; FEMALE; HUMANS; KIDNEY DISEASES; MALE; ULTRASONOGRAPHY, DOPPLER, COLOR;

EID: 36749091859     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm418     Document Type: Article

References (30)

1. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701
2. Levey A, Beto J, Coronado B et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know, what do we need to learn, where do we go from here? Am J Kidney Dis 1998; 32: 853-906
3. Shik J, Parfrey P. The clinical epidemiology of cardiovascular disease in chronic kidney disease. Curr Opin Nephrol Hypertens 2005; 14: 550-557
4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
5. Vanholder R, Massy Z, Argiles A et al. Chronic kidney disease as a cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056
6. Ritz E, McClellan W. Overview: increased cardiovascular risk in patients with minor renal dysfunction: an emerging issue with far-reaching consequences. J Am Soc Nephrol 2004; 15: 513-516
7. Deanfield J, Donald A, Ferri C et al. Endothelial function and dysfunction. Methodological issues for assessment in the different vascular beds: a statement by the working group on endothelin and endothelial factors of the European society for hypertension. J Hypertens 2005; 23: 7-17
8. Guerin A, Pannier B, Marchais S, London G. Cardiovascular disease in the dialysis population: prognostic significance of arterial disorders. Curr Opin Nephrol Hypertens 2006; 15: 105-110
9. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risk modeling approach. J Am Soc Nephrol 2005; 16: 2449-2455
10. Knight E, Rimm E, Pai J et al. Kidney dysfunction, inflammation, and coronary events: a prospective study. J Am Soc Nephrol 2004; 15: 1897-1903
11. Morange P, Simon C, Alessi MC et al. Endothelial cell markers and the risk of coronary heart disease. Circulation 2004; 109: 1343-1348
12. Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005; 16: S83-S88
13. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population. Edinburgh Artery Study. Circulation 2005; 112: 976-983
14. Annuk M, Soveri I, Zilmer M, Lind L, Hulthe J, Fellstrom B. Endothelial function, CRP and oxidative stress in chronic kidney disease. J Nephrol 2005; 18: 721-726
15. Oberg BP, McMenamin E, Lucas FL et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65: 1009-1016
16. Yilmaz MI, Saglam M, Caglar K et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 2006; 47: 42-50
17. Fulton R, McDade RL, Smith PL, Kienker LJ, Kettman JR,Jr. Advanced multiplexed analysis with the Flow metrix system. Clin Chem 1997; 43: 1749-1756
18. Khan SS, Smith MS, Reda D, Suffredini AF, McCoy JP Jr. Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytochemistry B Clin Cytom 2004; 61: 35-39
19. Koenig W, Khuseyinova N, Baumert J et al. Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results of the MONICA/KORA Augsburg case-cohort study, 1984-2002. Atheroscl Thromb Vasc Biol 2006; 26: 2745-2751
20. Lee W, Allison M, Kim D, Song C, Barrett-Connor E. Association of interleukin-6 and C-reactive protein with subclinical carotid atherosclerosis (the Rancho Bernardo Study). Am J Cardiol 2007; 99: 99-102
21. Honda H, Qureshi AR, Heimburger O et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006; 47: 139-148
22. Thusen von der JH, Kuiper J, van Berkel T, Biessen E. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev 2003; 55: 133-166
23. Lutten A, Lutgens E, Manderveld A et al. Loss of MMP-9 or MMP-12 protects ApoE-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation 2004; 109: 1408-1414
24. Ferroni P, Basili S, Martini F et al. Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J Investig Med 2003; 51: 295-300
25. Fitzsimmons PJ, Forough R, Lawrence ME et al. Urinary Urinary levels of matrix metalloproteinase 9 and 2 and tissue inhibitor of matrix metalloproteinase in patients with coronary artery disease. Atherosclerosis 2006; DOI: 10.1016/j.atherosclerosis.2006.07.027
26. Sundstrom J, Vasan R. Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events. Curr Opin Lipidol 2006; 17: 45-53
27. Vaughan D. PAI-1 and atherothrombosis. J Thromb Haemost 2005; 3: 1879-1883
28. Lucerna M, Zernecke A, de Nooijer R et al. Vascular endothelial growth factor-A induces plaque expansion in ApoE knockout mice by promoting de novo leukocyte recruitment. Blood 2007; 109: 122-129
29. Trape J, Morales C, Molina R et al. Vascular endothelial growth factor serum concentrations in hypercholesterolemic patients. Scand J Clin Lab Invest 2006; 66: 261-267
30. Roy H, Bhardwaj S, Babu M et al. VEGF-A, VEGF-D, VEGF receptor-1, VEGF receptor-2, NF-kB, and RAGE in atherosclerotic lesions of diabetic Watanabe heritable hyperlipidemic rabbits. FASEB J 2006; 20: 2159-2161